This educational program is intended for oncology nurses, nurse practitioners, clinical nurse specialists, and other healthcare professionals who care for patients with solid tumors.
The goal of this activity is to improve the knowledge, confidence, and competence of oncology nurses, nurse practitioners, and clinical nurse specialists to apply and explain available clinical data on novel and emerging therapies to individualize care for patients with solid tumors on or eligible for treatment with TROP2-targeted therapies.
Upon completion of this activity, participants should be able to:
Compare the unique mechanism of action between the antibody–drug conjugates sacituzumab govitecan and datopotamab deruxtecan to each other and cytotoxic chemotherapy
Evaluate individualized treatment strategies with ADCs targeting TROP2 for patients with breast cancer and NSCLC considering recent clinical data and approved indications
Explain to patients the role of TROP2-targeting ADCs after disease progression on targeted therapeutics or immune checkpoint inhibitor therapies
Manage patients experiencing adverse events associated with ADCs targeting TROP2, including assessment of physical complaints, radiologic imaging, and lab value interpretation
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Elise Hitron, MSN, FNP-C, has no relevant financial relationships to disclose.
Srigowri Kota, MSN, BA, APRN, AGNP-C, OCN, has no relevant financial relationships to disclose.
Neelima Vidula, MD: researcher (paid to institution): Daehwa, Merck, Novartis, Pfizer, Radius; consultant/advisor/speaker: Aadi, Gilead, Stemline, TerSera.
The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.
Participation in this self-study activity should be completed in approximately 1.25 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from June 22, 2023, through June 21, 2024:
You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.
This program has been made available online.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.25 contact hours.